Skip to main content

Table 2 Literature analysis regarding hepatectomy for liver metastases from gastric cancer

From: Surgical treatment of liver metastases of gastric cancer: state of the art

Author year n Period Resection criteria Resectability rate % S/M TG/STG Major/Minor liver surgery Solitary Multiple Uni/Bilob R1% Overall survival % 1, 3, 5 years Long-term survivors Recurrence Follow-up (months)
1994 [30] 21   No extrahepatic No carcinosis R0 Na 13/8 Na   14 7 0 19 19% (4)   
1997 [43] 21   No extrahepatic No carcinosis R0 Na 11/10   5/16 7 14 11/3 Na 45 19 11 24% (5) 76.1% n
2001 [23]               
  17 1990-1997 No extrahepatic            
No carcinosis               
R0 Na 7/10 na 6/11 8 9 4/5 18% 47 22 0 0 76% Na    
2001 [9]               
  40 1975-1999 No extrahepatic            
No carcinosis               
R0 Na 18/22 19/21 21/19 19 21         
5/16 0 70 28 18 15% (6) 75% 88          
2001 [45]               
  10 1979-1999 Na Na 3/7 3/7 6/4 6 4      
2/2 Na 60 20 20 10% (1) 80% 10-240          
2002 [33]               
  15 1980-1999 No extrahepatic            
No carcinosis               
R0 Na 10/5 9/6 3/12 8 7         
2/5 33 35.7 14.3 0 0 90% Na          
2002 [31]               
  10 1981-1998 No extrahepatic            
≤ 3 segments 15.6% 7/3 Na 6/4 5 5         
4/1 40% 65 38 20 20% (2) 80% 1-68          
2002 [28]               
  19 1986-1999 No extrahepatic            
No carcinosis               
R0 17% 13/6 na 7/12 10 9         
2/7 0 77 34 34 14% (3) 74% Na          
2003 [25]               
  22 1985-2001 No extrahepatic            
No carcinosis               
R0 8% 12/10 10/12 3/19 16 6         
1/5 0 73 38 38 20% (5) 68% Na          
2003 [41]               
  36 1979-2001 Na Na 16/20 17/19 10/16 Na Na 0 64, 43, 26 11% (4) 83.3% Na
2005 [29]               
  11 1988-1996 No extrahepatic            
No carcinosis               
Solitary nodules               
R0 Na 8/3 Na 2/9 11 0 0 73, 42, 27 18% (2) 80 Na    
2007 [34]               
  42 1985-2005 No extrahepatic            
No carcinosis               
R0 17% 20/22 Na 7/35 29 13 0 76, 48, 42 20% (8) 67% 1-86    
2007 [44]               
  37 1990-2005 No extrahepatic            
R0               
No carcinosis 12% 16/21 10/27 5/32 21 16         
9/7 14% 60 27 11 6% (2) 81% Na          
2008 [24]               
  24 1988-2002 No carcinosis            
R0 Na 15/9 Na 8/16 13 11         
5/6 25% 38, 16, 10 8% (2) 65% 1-67          
2008 [40]               
  18 1989-2004 No extrahepatic            
R0               
Hepatic function Na 11/7 8/10 4/14 14 14 Na 56.3, 36.5, 27 17% (3) Na 2-200    
2008 [37]               
  22 1995-2005 No extrahepatic            
No carcinosis               
R0               
Hepatic function 7.5% 18/4 7/15 3/19 18 4         
3/1 Na 77 30.4 23 15% (3) 63.6% 1-106          
2009 [47]               
  17 1991-2005 No extrahepatic            
No carcinosis               
≤ 5 lesions               
R0 Na 9/8 Na 3/14 Na Na 0 30.8 25% (4) 70.5% 1-117    
2009 [50]               
  73              
(11)* 1990-2004 R0             
No extrahepatic               
metachronous 15.1% 0/11 Na 1/10 8 3 0 81, 30, 20 18.2% (2) 63% 4-86    
2009 [47] 72              
(12)* 1991-2005   16.6% 12/0 Na 4/8 9 3 1 57, 43, 43 20% (3) Na Na  
Choi 2010               
  14 1986-2007 No extrahepatic            
No carcinosis               
R0 Na 0/14 Na 4/10 9 5         
2/3 0 67 38.3 8% (1) 63% Na          
Tsujmoto 2010               
  17 1980-2007 No extrahepatic            
No carcinosis               
Unilobar               
R0 Na 9/8 Na 6/11 13 4 Na 31 30% (5) 70% Na    
Our data               
2012 21 1998-2007 No extrahepatic            
No carcinosis               
R0 31% 12/9 10/11 4/17 12 9         
4/5 10% 68 31 19 14.2% (3) 66% 6-90          
  1. H1, Metastases limited to one lobe; H2, few scattered metastases in both liver lobes; H3, numerous scattered metastases in both lobes; M, Metachronous; mets, metastases; Na, not available; S, Synchronous; STG, Subtotal gastrectomy; TG, Total gastrectomy.
  2. Number of patients resected on a total of patients with LMGC.